Despite showing promise as an anti-cancer therapy, either intrinsic or acquired resistance to HDAC inhibitors is commonly observed in sub-populations of cancer cells, with acquired cross-resistance to other anti-cancer drugs a major problem in this therapeutic strategy [99,100,101]. The gene discussed is HDAC9; the disease is cancer.